Home / Executive Moves / Parsons Names Vice Chairman Tom Roell to Interim Federal Leadership Post

Parsons Names Vice Chairman Tom Roell to Interim Federal Leadership Post

Tom Roell
Tom Roell

Thomas “Tom” Roell, vice chairman and chief risk adviser at Parsons Corp., has been appointed interim president of the Pasadena, California-based engineering and construction services contractor’s federal business unit and will maintain his other current roles for the company.

Parsons said Wednesday Roell will continue to be based at the company’s global headquarters in Pasadena and announced the move nearly seven months after it realigned into a five-unit business structure that includes the federal organization which works with agencies in the defense, environmental, infrastructure, security and intelligence services arenas.

A Parsons spokesperson subsequently confirmed to GovCon Wire that former federal unit president Mary Ann Hopkins has left the company.

(Aug. 25 Editor’s Note: Please click here for our coverage of Hopkins’ appointment to an executive role at Amsterdam-based engineering and design consultancy services provider Arcadis)

Roell joined Parsons in 2003 and his career at the company includes time in roles such as group executive for operations and risk and president of the former infrastructure and technology group.

The company says he is a 45-year engineering and construction industry veteran and has held other senior executive roles at government, environmental and power organizations.

Check Also

F5 to Buy Shape Security for $1B; Francois Locoh-Donou Quoted

F5 Networks (Nasdaq: FFIV) has agreed to acquire Santa Clara, Calif.-based Shape Security for approximately $1B in cash as both companies aim to help government and enterprise customers secure digital experience with integrated offerings.

Paratek Secures $169M Anthrax Antibiotic Development Contract Under HHS Project BioShield

The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.